Navigation Links
Delcath Announces Agreement With Istituto Nazionale Tumori Fondazione G. Pascale for Further Expansion of CHEMOSAT in Italy
Date:3/27/2012

he United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the future use and adoption of the CHEMOSAT system by the Istituto Nazionale Tumori Fondazione G. Pascale, patient outcomes from CHEMOSAT procedures, future initial launch and training agreements with other cancer centers in Europe, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
2. Delcath Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
3. Delcath Announces First CHEMOSAT Procedures in Germany
4. Delcath Announces Agreement With University Medical Center Schleswig-Holstein for Use of Its Hepatic CHEMOSAT Delivery System
5. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
6. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
7. Delcaths Ireland Operations Achieves ISO 13485 Certification
8. Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
9. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
10. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
11. Delcath to Present at the Lazard Healthcare Conference on November 15
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces ... is available in its catalogue: ... Control (Sterilization, Disinfection, Testing and Treatment) ... Given the cost of ... has increased for solutions that can ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... U.S. IVD Industry http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... Care Act" (H.R. 3590) is complex legislation that ... many of its provisions are beginning to take ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... South Korea, Feb. 25 Dong-A PharmTech Co., ... Pharma, has initiated,a 200 patient, phase 2 proof ... udenafil, a long acting phosphodiesterase type 5 inhibitor, ... European,study is designed to investigate the safety and ...
... Enterprise Intelligence Systems to Healthcare Market, ... #1841 --,Harris Corporation (NYSE: HRS ), ... joined forces with Cancer Treatment,Services International (CTSI) ... oncology. Harris will provide advanced imaging and ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
(Date:8/20/2014)... A common approach to treating kidney failure ... improve survival chances for people who suddenly developed the ... University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive ... kidney failure, may not provide a definitive benefit to ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Quincy Bioscience, ... Inc. 500|5000 list of the fastest growing private ... year. Ranking at No. 2,941, Quincy Bioscience is honored ... in the United States. , Quincy Bioscience is manufacturer ... apoaequorin – a protein originally discovered in jellyfish and ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The non-small ... increase considerably in the offing across the top 8 ... of 2013 to around USD 8 billion by 2020-end, ... The growth is projected to be driven by innovative ... is currently lacking efficient treatment, unlike the non-squamous segment. ...
(Date:8/20/2014)... By Steven Reinberg ... -- A rare birth disorder that dismantles a baby,s immune ... study of more than 3 million infants says. This ... for the life-threatening but treatable condition known as severe combined ... "People were made aware of this condition by the boy ...
(Date:8/20/2014)... -- New research reveals that, long ago, sea mammals ... of the infectious disease known as tuberculosis. Ancient ... seals and sea lions, who then spread it to ... to an international team of researchers. "Tuberculosis is ... This study and further research will help us understand ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2
... , MASON, Ohio, Aug. 10 ... physicians representing the Women,s Dermatologic Society (WDS) will provide ... enjoying the Western & Southern Financial Group Master,s and Women,s ... a.m.-5:00 p.m. Led by board-certified dermatologist Allison Moosally, MD (Cleveland), ...
... PHILADELPHIA, August 10 , ... of System,s,Nine-Year "Journey to Excellence"; Elsevier Becomes Primary Information,Source ... http://www.elsevier.com ), a world leader in healthcare and,medical publishing ... of the top 10 Catholic health systems in the ...
... August 10 , - ... Help,Prevent Costly Mistakes; Hospitals Benefit From Averting the Reimbursement,Losses ... in healthcare and medical publishing and online,solutions, today announced ... Consult designed to help nurses prevent the 10 "Never ...
... ... US Drug Watchdog is intensifying its national efforts to get the word out ... Remedy Swabs. According to the group, "Our reasons are pretty simple. We fear ... has said, use of the products could result in a loss of taste, ...
... ... ... Tucson, Arizona is home to a dense Hispanic population. In recognition of September 15th ... word throughout the local Hispanic community that colorectal pre-screening can save lives., , , ...
... ... the publicly available iHOP database enables researchers to quickly and effectively use this invaluable ... ... of a new tutorial suite for iHOP, or Information Hyperlinked Over Proteins. iHOP ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 3Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 4Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:The US Drug Watchdog Calls Zicam Nasal Gel Or Zicam Swabs A National Disaster That May Have Caused People To Lose Their Sense Of Smell 2Health News:Hispanics at High Risk for Colorectal Cancer 2Health News:Hispanics at High Risk for Colorectal Cancer 3Health News:New Online Tutorial for iHOP from OpenHelix 2Health News:New Online Tutorial for iHOP from OpenHelix 3
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
... Adjustable Neck Flange Hyperflex™ Tracheostomy TubesSimilar ... tube features the more traditional and ... Aire-Cuf® Adjustable Neck Flange Hyperflex™ Tracheostomy ... wedge, and obturator/introducer device., ,NOTE: ...
... for easy ventilator circuit attachment with or ... tubes are available in five adult sizes, ... system allows quick identification and correct sizing ... ,The Portex® line of D.I.C.® tracheostomy tubes ...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: